about
PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivoCytoplasmic calcium measurement in rotavirus enterotoxin-enhanced green fluorescent protein (NSP4-EGFP) expressing cells loaded with Fura-2.Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trialCD74 interferes with the expression of fas receptor on the surface of lymphoma cellsFAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.Junctional Adhesion Molecules (JAMs) are differentially expressed in fibroblasts and co-localize with ZO-1 to adherens-like junctions.Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosisCell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ.Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments.Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells.Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex.Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.Milatuzumab - a promising new immunotherapeutic agent.HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer.Lymphoid hyperplasia and lymphoma in KSHV K1 transgenic mice.Targeting Wnt pathway in mantle cell lymphoma-initiating cells.Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma.Targeting nucleolin for better survival in diffuse large B-cell lymphoma.Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia?Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical diseaseCell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γA pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis
P50
Q24317781-A9B07DB4-D657-4881-9653-AAC1DB6567B5Q30938272-B07FECB2-9F18-4D26-B8B4-F043C307AA4BQ33168449-A3AA28BA-A0E9-4706-9FFC-2316FDAAB3A3Q33416554-77D1B0B2-0E98-4B0E-97C5-4428758189A7Q33429980-368E33BD-EC33-4243-94E8-AD092A682F30Q34409837-86860E6E-EFE7-4286-A632-20730DF45B9EQ34419383-26CEF215-4717-4B9C-8459-F3A446D3EFFBQ34652725-7B4B91C2-DABA-43F5-B005-F6518BA543A9Q35147669-EE88C624-839D-45AC-8257-27445586C524Q36269050-9ABDC1F9-A0C5-4243-B942-0E9E9F216117Q36295757-12FF08F7-284E-49A3-9FE8-DD9DA95C4AC8Q36333522-A9D19E9C-B113-44EB-801D-E8087FF3A7ADQ36453798-B056B83B-1391-4580-9D37-1105ADF918B5Q36907845-6A6D78A6-9D27-48C1-848E-D519BCF72621Q37613316-760F4C0B-0D49-4B3E-B7F2-358F08E0DA7AQ37646791-6D48390D-F32A-48E1-862B-528103F90500Q38910084-4D5DC6FD-5EBE-4423-A95A-C2D41CA0D9BCQ42183981-93101853-D169-4CF4-A2AB-B0D101DD5E93Q42558443-D912872A-2140-403C-97DA-B09DECD3E5B0Q49166966-E0F2BF6C-02A7-40F7-AA6E-06878A7E0BD3Q52583133-8664C8F7-59F6-4803-A585-B3CCFEEEFEFCQ53716139-4DC01E62-BD8F-4FA9-AD9B-D9099DF8066DQ73492078-D7B19119-88DD-4502-8BA7-F2FC7C4D140EQ85604183-912CEB10-4473-4481-99C4-5A8CCA4D8F42Q92576211-FED192CB-4242-4A21-AB99-958030DDDD27
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Z Berkova
@ast
Z Berkova
@en
Z Berkova
@es
Z Berkova
@nl
Z Berkova
@sl
type
label
Z Berkova
@ast
Z Berkova
@en
Z Berkova
@es
Z Berkova
@nl
Z Berkova
@sl
altLabel
Z Berkova
@en
prefLabel
Z Berkova
@ast
Z Berkova
@en
Z Berkova
@es
Z Berkova
@nl
Z Berkova
@sl
P1053
E-9010-2018
P106
P1153
57201695473
P31
P3829
P496
0000-0001-8196-6517